ClinicalTrials.gg
RecruitingNCT07674615Updated Nov 19, 2026

IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

A Phase 1 interventional study of Sacituzumab govitecan monotherapy in Epithelial Ovarian Cancer, Fallopian Tube Cancers and Primary, sponsored by Shanghai Gynecologic Oncology Group. Recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Gynecologic Oncology Group · Phase 1, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 71 studies in Carcinoma, Ovarian Epithelial with a site in China — 30 open to participants now, 37 under way, 11 of them phase 3. Carcinoma, Ovarian Epithelial · China.

Planned enrollment
47th of 53
19 · median 94
Started
2026
with 9 others
Phase 1
7 of 71
3 open now
Primary completion
2027-06
later than 20 of 36 live
Registered
67th of 71
by date
Lead sponsor
7 of 71
Shanghai Gynecologic Oncology Group

Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, this one is the 47th largest by planned enrollment of the 53 interventional ones that give a count, is one of 10 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 20 of the 36 other live ones, and was the 67th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

30 of the 71 studies in Carcinoma, Ovarian Epithelial with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Ovarian Epithelial with a site in China, or all of them as a file.
02

Study summary

To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.

Read the detailed description

Trophoblast cell surface antigen-2 (TROP-2) is overexpressed in a variety of epithelial-derived tumor tissues and represents a promising antitumor therapeutic target. Novel antibody-drug conjugates (ADCs) targeting TROP-2, such as IMMU-132 (SG), Datopotamab Deruxtecan (Dato-DXd), and Sacituzumab Tirumotecan (MK-2870), are under active development. In ovarian cancer, efficacy data for TROP-2 ADCs mainly derive from pan-solid tumor clinical studies. TROP-2 expression exhibits intratumoral heterogeneity. Currently, there is no standardized or internationally accepted guideline for evaluating TROP-2 expression. TROP-2 expression status can be assessed using the H-score scoring system: 0-100 as low expression, 100-200 as moderate expression, and >200 as high expression. An exploratory analysis of the ASCENT study in triple-negative breast cancer, which categorized TROP-2 expression as high, moderate, or low based on H-score, found that patients with high expression had double the efficacy compared to those with moderate expression (44% vs 22%). Therefore, subsequent studies are warranted to explore effective screening criteria for TROP-2 ADC drugs to achieve more precise diagnosis and treatment. Our center has observed that among 3 patients with heavily pretreated recurrent ovarian cancer and high TROP-2 expression in tumor tissue, 1 achieved a complete response (CR) and 2 achieved partial responses (PR) following SG monotherapy. Safety was favorable, with main side effects being grade 1-2 gastrointestinal reactions and no grade 3-5 adverse reactions. Accordingly, this study will prospectively observe the efficacy of IMMU-132 monotherapy in patients with advanced or recurrent ovarian cancer characterized by high TROP-2 expression in tumor tissue.

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancers
  • Primary
  • Primary Peritoneal Carcinoma

Keywords

  • Ovarian cancer
  • TROP2
  • Antibody-drug conjugates
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and ≤ 80 years;
  • confirmed advanced or recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer;
  • Recurrent patients meeting one of the following two conditions:

Disease recurrence or progression after at least one prior platinum-based chemotherapy regimen, with disease progression occurring less than 6 months from the last dose of platinum-based chemotherapy;

  • Disease recurrence or progression after at least three prior platinum-based chemotherapy regimens, with disease progression occurring ≥ 6 months from the last dose of platinum-based chemotherapy, and who are unable to receive standard platinum-based chemotherapy;
  • Patients with advanced epithelial ovarian cancer presenting with hematogenous , who are unable to receive standard treatment, with an estimated of more than 3 months but approximately not exceeding 12 months with current therapy;
  • Have per 1.1 criteria (Appendix A) or diagnosis of recurrence/disease progression per GCIG criteria;
  • Known BRCA (Breast Cancer Gene) and HRD (Homologous Recombination Deficiency) status;
  • Have available paraffin-embedded or fresh tumor tissue for TROP-2 testing;
  • Tumor tissue TROP-2 H-score > 200;
  • (ECOG) performance status score of 0-2;
  • Adequate bone marrow hematopoietic function and organ function, allowing the patient to receive treatment;
  • Patients must have had at least a 2-week interval from prior therapy (chemotherapy, agents including small molecule inhibitors, endocrine therapy, immunotherapy, and/or radiotherapy) or major surgery;
  • Patients must have had at least a 2-week interval from high-dose systemic (however, low-dose corticosteroids \< 20 mg prednisone or its equivalent are permitted);
  • Patients must have recovered from acute toxicity due to prior therapy to Grade 1 or below;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received topoisomerase I inhibitor therapy;
  • Patients with known to the study drug, its metabolites, or formulation ;
  • Patients requiring ongoing treatment or prior use of any prohibited medications (e.g., UGT1A1 inhibitors);
  • Patients with Gilbert's syndrome;
  • Patients with other uncontrolled concurrently or within 5 years, whose treatment would interfere with the current therapy for recurrent ovarian cancer or affect the prognosis of this treatment. Carcinoma in situ and breast cancer (without active disease or signs of recurrence) are excluded;
  • Patients with a history of hemorrhage, bowel obstruction, or gastrointestinal perforation within 6 months prior to the start of study treatment, with an estimated of less than 3 months;
  • Patients with a history of significant cardiac disease within 6 months, such as uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure ( Class III-IV), or clinically significant arrhythmias requiring antiarrhythmic therapy (except stable atrial fibrillation);
  • Patients with known clinically significant active (COPD) or other moderate-to-severe chronic respiratory disease within 6 months;
  • Patients with known active central nervous system (CNS) and/or carcinomatous meningitis. Patients with treated may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose, have all neurological symptoms returned to baseline, have no evidence of new or enlarging brain metastases, and are on a daily dose of ≤ 20 mg prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability;
  • Patients with uncontrolled seizure history or active neurologic disorders; Patients with known -1 or HIV-2 (or HIV-1/2 antibody positive) with detectable viral load, or those taking medications that may interfere with SN-38 metabolism;
  • Patients with active or . For patients with a history of HBV or HCV, those with detectable viral load will be excluded;
  • Patients with known bleeding diathesis or active bleeding disorders;
  • Patients with active ≥ Grade 2 anorexia, nausea, or vomiting, and/or signs of bowel obstruction;
  • Patients with other concurrent medical or psychiatric conditions that, in the investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations;
  • Patients with any unstable medical problems (including the cardiac issues mentioned above, active treatment for symptomatic pulmonary embolism, stroke, renal or hepatic insufficiency, active infection/sepsis requiring intravenous antibiotics);
  • Any medical condition that, in the investigator's opinion, poses an undue risk to the patient's participation in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    TROP2-ADC group

    IMMU-132 monotherapy at a dose of 10 mg/kg administered intravenously on Days 1 and 8 of each 21-day cycle.

    Drug: Sacituzumab govitecan monotherapy

Interventions

  • DrugSacituzumab govitecan monotherapy

    Sacituzumab govitecan monotherapy at a dose of 10 mg/kg administered intravenously on Days 1 and 8 of each 21-day cycle.

This study also gives Sacituzumab govitecanStudies of Sacituzumab govitecanSacituzumab govitecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective response rate

    The proportion of patients with complete response (CR) and partial response (PR) assessed by the investigator in accordance with the RECIST 1.1 criteria

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 30 non-industry phase 1 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 54. This study's planned 9 months is below that.

Counting every sponsor, half of 56 studies reached it within 44 months; a quarter within 34 and three quarters within 81.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 29, 2026
StartActual
Sep 2, 2026was Jul 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
Zhongshan Hospital Fudan University is now Recruiting
Nov 19, 2026
Start date
Jul 1, 2026→Sep 2, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    Zhongshan Hospital Fudan University is now Recruiting
    Start date Jul 1, 2026→Sep 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07674615
Lead sponsor
Shanghai Gynecologic Oncology Group
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Sep 2, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Yulian Chen
Contact
emma_serendipity@163.com
86-21-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion